Pulike Biological Engineering Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Wei Hu

Geschäftsführender

CN¥2.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	13.5yrs
Eigentum des Geschäftsführers	1.2%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.8yrs

Jüngste Management Updates

Recent updates

Pulike Biological Engineering's (SHSE:603566) Weak Earnings May Only Reveal A Part Of The Whole Picture

Sep 04

Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump

May 21

Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024

Apr 28

Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E

Mar 21

Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Feb 28

Geschäftsführer

Wei Hu (51 yo)

13.5yrs

Amtszeit

CN¥2,634,900

Vergütung

Mr. Wei Hu is Director of Pulike Biological Engineering, Inc. since March 26, 2011 and serves as its Managing Director. Mr. Hu was Deputy General Manager and Non-Independent Director of Pulike Biological E...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Wei Hu	MD & Director	13.5yrs	CN¥2.63m	1.22% CN¥ 54.3m
Lian Feng Pei	CFO, Accounting Supervisor & Director	13.5yrs	CN¥1.05m	0.40% CN¥ 17.8m
Yong Jun Song	Deputy GM & Non-Independent Director	13.5yrs	CN¥1.17m	0.87% CN¥ 38.9m
Rui Zhao	Secretary of the Board & Director	8.3yrs	CN¥854.80k	0.0065% CN¥ 290.5k
Xian Sheng Zhang	Independent Director	1.4yrs	CN¥61.10k	keine Daten
Changqing Sun	Non-Independent Director	no data	keine Daten	4.89% CN¥ 218.0m
Xu Ke Zhang	Chairman of the Board	13.5yrs	CN¥1.19m	31.81% CN¥ 1.4b
Dechao Qin	Vice Chairman	7.3yrs	CN¥2.63m	0.058% CN¥ 2.6m
Xin Zou	Independent Director	7.3yrs	CN¥34.90k	keine Daten
Chuduan Wang	Independent Director	1.4yrs	CN¥61.10k	keine Daten
Bo Zhang	Independent Director	no data	CN¥34.90k	0.0031% CN¥ 139.9k
Xiaoli Wang	Supervisor	1.4yrs	keine Daten	0.0027% CN¥ 121.2k

7.8yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrener Vorstand: 603566Die Vorstandsmitglieder gelten als erfahren (7 Jahre durchschnittliche Amtszeit).

Pulike Biological Engineering Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Pulike Biological Engineering, Inc., Annual General Meeting, May 16, 2024

Recent updates

Investor sentiment improves as stock rises 17%

Now 21% undervalued after recent price drop

Pulike Biological Engineering's (SHSE:603566) Weak Earnings May Only Reveal A Part Of The Whole Picture

Price target decreased by 13% to CN¥16.24

Now 22% undervalued after recent price drop

Price target decreased by 8.3% to CN¥18.56

Pulike Biological Engineering, Inc. to Report First Half, 2024 Results on Aug 30, 2024

Dividend of CN¥0.40 announced

Investor sentiment deteriorates as stock falls 20%

Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump

Investor sentiment improves as stock rises 19%

Now 26% overvalued after recent price rise

Consensus revenue estimates fall by 13%

Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024

First quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.19 in 1Q 2023)

Pulike Biological Engineering, Inc., Annual General Meeting, May 16, 2024

Pulike Biological Engineering, Inc. to Report Q1, 2024 Results on Apr 26, 2024

Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E

Price target decreased by 8.0% to CN¥25.07

Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorates as stock falls 15%

Pulike Biological Engineering, Inc. to Report Fiscal Year 2023 Results on Apr 26, 2024

Pulike Biological Engineering, Inc. (SHSE:603566) announces an Equity Buyback for CNY 200 million worth of its shares.

Pulike Biological Engineering, Inc. (SHSE:603566) announces an Equity Buyback for CNY 200 million worth of its shares.

Pulike Biological Engineering, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Price target decreased by 7.9% to CN¥28.23

New major risk - Earnings quality

Pulike Biological Engineering, Inc. to Report First Half, 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 11%

First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.12 in 1Q 2022)

Price target decreased to CN¥28.05

Consensus forecasts updated

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.21 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.24 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥22.55

Investor sentiment improved over the past week

Price target decreased to CN¥26.37

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.13 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.20 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.18 in 1Q 2020)

New 90-day low: CN¥20.02

Full year 2020 earnings released: EPS CN¥0.68 (vs CN¥0.34 in FY 2019)

Revenue and earnings beat expectations

New 90-day low: CN¥20.15

New 90-day low: CN¥21.50

New 90-day low: CN¥23.20

New 90-day low: CN¥23.82

Third quarter earnings released

New 90-day high - CN¥31.00

First half earnings released

New 90-day high - CN¥29.65

Pulike Biological Engineering, Inc. to Report First Half, 2020 Results on Aug 31, 2020

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter